Universität zu Köln

Baues, C., Semrau, R., Gaipl, U. S., Broeckelmann, P. J., Rosenbrock, J., Engert, A. and Marnitz, S. (2017). Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma. Strahlenther. Onkol., 193 (2). S. 95 - 100. MUNICH: URBAN & VOGEL. ISSN 1439-099X

Full text not available from this repository.

Abstract

Background Patients with classical Hodgkin's lymphoma (cHL) have a good prognosis even in advanced stages. However, combined chemo- and radiotherapy, as the standard of care, is also associated with treatment-related toxicities such as organ damage, secondary neoplasias, infertility, or fatigue and long-term fatigue. Many patients suffer from this burden although their cHL was cured. Therefore, the efficacy of immune checkpoint inhibitors like anti-PD1/PD-L1 antibodies in the treatment of solid cancers and also in HL offers new options. A remarkable and durable response rate with a favorable toxicity profile was observed in heavily pretreated cHL patients. Methods Planning to perform prospective randomized clinical trials in the content of radio-immune treatment in patients with Hodgkin's lymphoma (HL), we transferred the results of preliminary clinical studies and basic research in clinical relevant study concepts. Results Based on these promising early phase trial data, the German Hodgkin Study Group (GHSG) will investigate innovative treatment regimens in upcoming phase II trials. Conclusion The therapeutic efficacy and potential synergies of anti-PD1 antibodies in combination with chemo- or radiotherapy will be investigated in various settings of HL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Baues, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Semrau, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gaipl, U. S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Broeckelmann, P. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rosenbrock, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Marnitz, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-241030
DOI:	10.1007/s00066-016-1050-4
Journal or Publication Title:	Strahlenther. Onkol.
Volume:	193
Number:	2
Page Range:	S. 95 - 100
Date:	2017
Publisher:	URBAN & VOGEL
Place of Publication:	MUNICH
ISSN:	1439-099X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANTITUMOR IMMUNE-RESPONSES; RADIOTHERAPY; PD-1; INTENSITY; INDUCTION; NIVOLUMAB; SURVIVORS; THERAPY; FATIGUE; TRIAL Multiple languages Oncology; Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24103